Health · Medical Research · 2 hrs ago

Imagion secures first site for MagSense breast cancer trial

Imagion secures first site for MagSense breast cancer trial

Imagion Biosystems has signed its first US trial site for a study of its MagSense imaging agent in HER2-positive breast cancer.

The site is Regis Clinical Research, an oncology-focused research organisation in Miami.

The Phase 1b/2 trial will assess MagSense as a diagnostic imaging agent for this breast cancer subtype.

MagSense uses targeted magnetic nanoparticles to enhance MRI images without radioactive tracers or ionising radiation.

The study will test safety, dosing and diagnostic performance in three parts, with interim analyses planned after the first two.

Seven other sites have been selected, and Imagion is working to finalise their contracts and activate them.

Recruitment is expected after site activation, and the trial is expected to take 18 to 24 months.

1 source

Related

What people are saying

Ward DetwilerImagion Biosystems, Inc. president
We are excited to have Regis as our first trial site under contract
via Stockhead
As an organisation focused on efficient study execution and with deep experience across oncology trials, Regis aligns with IBX’s focus on expediently advancing our clinical development goals.
via Stockhead